Saturday 17 October 2026
Export GRCE’s income statement to Excel — free account
Grace Therapeutics, Inc.
GRCE Healthcare Biotechnology
In the quarter to June 2026, EPS fell 333.3% and free cash flow fell 78.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.
1.89
0.06
−3.08%
Follow GRCE
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(13.15%) | (10.22%) | (11.94%) | (36.19%) | |
| (11.85%) | (9.22%) | (11.24%) | (33.74%) | ||
ROIC |
(17.01%) | (15.21%) | (14.76%) | (43.36%) | |
Return on Tangible Assets |
(48.67%) | (33.33%) | (51.13%) | (154.48%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.75) | (0.60) | (0.54) | (0.60) | |
Free Cash Flow |
(12.01) | (10.13) | (8.87) | (10.29) | |
| Other line items | |||||
Cash ROIC |
(15.08%) | (12.12%) | (10.97%) | (16.60%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
1.54 | 1.69 | 1.14 | 0.51 | |
Depreciation/Fixed assets |
0.50 | 0.64 | 0.88 | 1.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.75) | (0.60) | (0.54) | (0.60) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates